Samsung Biologics signed a contract with Modena for the OEM production of the Covid-19 vaccine on 22nd local time.

This contributes to Korea's emergence as a global hub for Covid-19 vaccine production and helps the Korean government continue to implement its "dual vaccine strategy" of importing vaccines and developing and producing them in-house.

This will make Modena the fourth vaccine produced domestically after AstraZeneca, Novavax, and Sputnik V.

Samsung Biologics will also become the first Korean company to produce mRNA vaccines. (Yonhap News Agency)